Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Source: 
Fierce Pharma
snippet: 

Less than a year after his release from a Pennsylvania prison, Martin Shkreli is taking flak from the Federal Trade Commission (FTC) over his “clear disregard for the law.”

The FTC on Friday asked a federal judge in the Southern District of New York to hold Shkreli in contempt, citing the ex-Turing CEO’s failure to hand over documents and sit for an interview as part of an investigation into whether his new company “Druglike” violates Shkreli’s lifetime ban from the pharmaceutical industry.